RxDoctor Payments Data

Rory Myer, MD

Ophthalmology · Ormond Beach, FLNPI 1023273398

Payments from drug & device makers

$4,846in general payments, 2019–2025

Across 163 payments — averaging $29.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • AbbVie$707
  • Biotissue Holdings Inc.$332
  • Sight Sciences, Inc.$292
  • Tarsus Pharmaceuticals, Inc.$188
  • Sun Pharmaceutical Industries Inc.$159
  • plus $619 from 14 others

What the payments were for

  • Consulting fees$1,05022%
  • Food & beverage$3,78578%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,846 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$746,766
Medicare patients
2,051
Services billed
7,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine215$234,672
XdemvyLotilaner55$103,529
XiidraLifitegrast78$77,824
Cyclosporine124$60,828
RocklatanNetarsudil Mesylat/Latanoprost34$19,683
LumiganBimatoprost31$18,673
Prednisolone Acetate326$15,414
CombiganBrimonidine Tartrate/Timolol29$13,734
ValacyclovirValacyclovir Hcl144$12,097
Latanoprost797$11,623
SimbrinzaBrinzolamide/Brimonidine Tart33$9,623
VevyeCyclosporine11$8,676
Fluorometholone80$8,014
RhopressaNetarsudil Mesylate13$6,698
Dorzolamide-TimololDorzolamide/Timolol/Pf51$6,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$707$267,078275 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$188$103,52955 claims
Bausch & Lomb Americas Inc.Xiidra$34$77,82478 claims
AlconSimbrinza$2,548$9,62333 claims
Harrow Eye, LLCVevye$134$8,67611 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax$19$4,61313 claims
Kala Pharmaceuticals, Inc.Inveltys$69$4,59213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Ormond Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →